Stockreport

FDA signs off on Phase 1/2 study of Celsion's GEN-1 in ovarian cancer; shares ahead 24% premarket [Seeking Alpha]

Celsion Corporation  (CLSN) 
Last celsion corporation earnings: 11/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.celsion.com/investor-relations
PDF FDA signs off on Phase 1/2 study of Celsion's GEN-1 in ovarian cancer; shares ahead 24% premarketNano cap Celsion (NASDAQ:CLSN) is up24% premarket on increased volume on [Read more]